Literature DB >> 25262803

Tankyrase inhibitors as therapeutic targets for cancer.

Ahmed Kamal, Sd Riyaz, Ajay Kumar Srivastava, Abdul Rahim1.   

Abstract

Tankyrase 1 and 2 belonging to the family of poly(ADP-ribosyl)ases play an important role in PARsylation by utilizing NAD+ as a substrate in order to generate ADP-ribose polymers. Tankyrases are involved in a number of cellular functions, that includes telomere homeostasis, mitotic spindle formation, vesicle transport linked to glucose metabolism, Wnt/β-catenin signalling, and viral replication. These roles of tankyrases in disease-relevant cellular processes have made them attractive drug targets. Recently, several inhibitors have been identified as potential clinical leads. The current review covers the progress, mechanism and binding modes of recently known Tankyrase inhibitors and discusses the rational approaches that were used to identify the tankyrase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25262803     DOI: 10.2174/1568026614666140929115831

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  8 in total

1.  Potential Use of Inhibitors of Tankyrases and PARP-1 as Treatment for Cancer and Other Diseases.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2016-02-01       Impact factor: 4.345

2.  Regulation of tankyrase activity by a catalytic domain dimer interface.

Authors:  Chen Fan; Nageswari Yarravarapu; Hua Chen; Ozlem Kulak; Pranathi Dasari; Jeremiah Herbert; Kiyoshi Yamaguchi; Lawrence Lum; Xuewu Zhang
Journal:  Biochem Biophys Res Commun       Date:  2018-07-26       Impact factor: 3.575

3.  From PARP1 to TNKS2 Inhibition: A Structure-Based Approach.

Authors:  Stefano Tomassi; Julian Pfahler; Nicola Mautone; Annarita Rovere; Chiara Esposito; Daniela Passeri; Roberto Pellicciari; Ettore Novellino; Martin Pannek; Clemens Steegborn; Alessandro Paiardini; Antonello Mai; Dante Rotili
Journal:  ACS Med Chem Lett       Date:  2020-02-03       Impact factor: 4.345

4.  TNKS inhibitors potentiate proliferative inhibition of BET inhibitors via reducing β-Catenin in colorectal cancer cells.

Authors:  Qian Wu; Yi-Fei Xuan; Ai-Ling Su; Xu-Bin Bao; Ze-Hong Miao; Ying-Qing Wang
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

5.  XAV939 inhibits the proliferation and migration of lung adenocarcinoma A549 cells through the WNT pathway.

Authors:  Chong Li; Xu Zheng; Yanyan Han; Yan Lv; Fu Lan; Jie Zhao
Journal:  Oncol Lett       Date:  2018-04-13       Impact factor: 2.967

Review 6.  Wnt/β-catenin signaling in cancers and targeted therapies.

Authors:  Fanyuan Yu; Changhao Yu; Feifei Li; Yanqin Zuo; Yitian Wang; Lin Yao; Chenzhou Wu; Chenglin Wang; Ling Ye
Journal:  Signal Transduct Target Ther       Date:  2021-08-30

7.  Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors.

Authors:  Donghui Qin; Xiaojuan Lin; Zhi Liu; Yan Chen; Zhiliu Zhang; Chengde Wu; Linlin Liu; Yan Pan; Sylvie Laquerre; John Emery; Jeff Fergusson; Kimberly Roland; Rick Keenan; Allen Oliff; Sanjay Kumar; Mui Cheung; Dai-Shi Su
Journal:  ACS Med Chem Lett       Date:  2021-05-13       Impact factor: 4.632

8.  The Adenoviral E1B-55k Protein Present in HEK293 Cells Mediates Abnormal Accumulation of Key WNT Signaling Proteins in Large Cytoplasmic Aggregates.

Authors:  Petter Angell Olsen; Stefan Krauss
Journal:  Genes (Basel)       Date:  2021-11-29       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.